# Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors

> **NCT02307227** · PHASE2 · COMPLETED · sponsor: **Centro di Riferimento Oncologico - Aviano** · enrollment: 46 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Paclitaxel
- **DRUG:** Epirubicin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02307227
- **Lead sponsor:** Centro di Riferimento Oncologico - Aviano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2009-04
- **Final completion:** 2014-04
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2014-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02307227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02307227, "Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02307227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*